Boston Scientific Touts Data On "Purpose-Built" Drug-Eluting Peripheral Stent
This article was originally published in The Gray Sheet
The firm's Eluvia paclitaxel eluting stent, design for peripheral arteries, showed positive results in data from a small trial presented April 28 at the Charing Cross International Symposium in London.
You may also be interested in...
The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.
An expert panel foresees increased adoption of digital tools in the OR, not just robotics. These tools help surgeons make more informed decisions and improve outcomes, but barriers remain.
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.